Join the Oncology Voice Network. Join for Free
My GOAL is to be a Medical Science Liaison
Medical Science Liaison pharmaceutical sales career progression networking in medical field MSL career advice

My GOAL is to be a Medical Science Liaison


Share This Article


Summary

In this episode, Jeremy McLemore shares his inspiring journey from pharmaceutical sales to becoming a Medical Science Liaison (MSL). Jeremy discusses his transition into the MSL role, detailing how he discovered the position and pursued it despite setbacks. He reflects on his experiences at Bristol Myers Squibb and AbbVie, highlighting the importance of networking, adaptability, and resilience in career progression. Jeremy also compares sales and MSL roles, offering insights into the unique challenges of each. He concludes with valuable advice for aspiring MSLs and shares his future goals.

Jeremy McLemore, Medical Science Liaison at AbbVie, discusses how his goal was to be an MSL and how he got there.

Jeremy shares….

How he approached his career from PharmD onward

The importance of being flexible and adaptable

Why it makes sense to consider a “starter” Industry role

How sales and field medical affairs differ (and how they are alike)

Click for Source
Medical Science Liaison, pharmaceutical sales, career progression, networking in medical field, MSL career advice

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2
OVN Avatar Guillaume Beinse, MD, Virgile Tellier, Valentin Charvet, MSc, Eric Deutsch, MD, PhD, Isabelle Borget, PharmD, PhD, Christophe Massard, MD, PhD., Antoine Hollebecque, MD, PhD, and Loic Verlingue, MD

Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2

Article
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
OVN Avatar Laleh Amiri-Kordestani & Richard Pazdur

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Article
Real-World Evidence in Oncology: Opportunities and Limitations
OVN Avatar Massimo Di Maio, Francesco Perrone, Pierfranco Conte

Real-World Evidence in Oncology: Opportunities and Limitations

Article
Accelerated drug approvals in oncology: Pros and cons
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Explore OVN